An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

PURPOSE: To determine ombrabulin’s maximum tolerated dose and dose recommended for Japanese patients with advanced solid tumors and to assess its antitumor activity and overall safety and pharmacokinetic profiles. METHODS: This was a multi-center, open-label, sequential-cohort, dose-escalation phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Murakami, H., Kurata, T., Onozawa, Y., Watanabe, J., Ono, A., Takahashi, T., Yamamoto, N., Fujisaka, Y., Kiyota, H., Hayashi, H., Tanaka, K., Nakagawa, K., Kuroda, S.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3931931/
https://ncbi.nlm.nih.gov/pubmed/24477603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2388-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados